Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 9/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.61 |
| ▸ | USP2 | O75604 | 7/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.59 |
| ▸ | TP53 | P04637 | 4/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.59 |
| ▸ | HPGD | P15428 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.51 |
| ▸ | HTR3B | O95264 | 1/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.51 |
| ▸ | HTR3A | P46098 | 1/20 | 0.51 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.51 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 7/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2818789 | 0.92 | HTR3E (0.58) | CYP2D6ALDH1A1CYP3A4USP2CYP1A2 | |
| SCHEMBL31276695 | 0.88 | CYP2D6 (0.54) | CYP2D6ALDH1A1CYP3A4USP2CYP1A2 | |
| SCHEMBL20842185 | 0.86 | CYP2D6 (0.60) | CYP2D6ALDH1A1CYP3A4USP2CYP1A2 | |
| SCHEMBL20455740 | 0.86 | CYP2D6 (0.60) | CYP2D6ALDH1A1CYP3A4USP2CYP1A2 | |
| SCHEMBL1426810 | 0.85 | CYP2D6 (0.82) | CYP2D6ALDH1A1CYP3A4USP2CYP1A2 | |
| SCHEMBL21026597 | 0.85 | CYP2D6 (0.56) | CYP2D6ALDH1A1CYP3A4USP2CYP1A2 | |
| SCHEMBL1778852 | 0.85 | CYP2D6 (0.69) | CYP2D6ALDH1A1CYP3A4USP2CYP1A2 | |
| SCHEMBL21963849 | 0.83 | ALDH1A1 (0.57) | CYP2D6ALDH1A1CYP3A4USP2CYP1A2 | |
| SCHEMBL31341893 | 0.83 | HTR3E (0.58) | CYP2D6ALDH1A1CYP3A4USP2CYP1A2 | |
| SCHEMBL1556835 | 0.83 | CHRNB4 (0.61) | CYP2D6ALDH1A1CYP3A4USP2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200048267-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-13 | — | — | US | disclosed |
| WO-2018141984-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2018-08-09 | — | — | WO | disclosed |
| WO-2013066729-A1 | AMINOPYRIMIDINONES AS INTERLEUKIN RECEPTOR-ASSOCIATED KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-05-10 | — | — | WO | disclosed |
| EP-2301936-A1 | SPIRODIAMINE-DIARYLKETOXIME DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2011-03-30 | — | — | EP | disclosed |
| US-20110071129-A1 | SPIRODIAMINE-DIARYL KETOXIME DERIVATIVE | MSD K.K. (JP) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071129-A1 | SPIRODIAMINE-DIARYL KETOXIME DERIVATIVE | MCHR2, MCHR1, ADRB2 | CYP2D6 74/4885ALDH1A1 409/4885CYP3A4 251/4885 |
| US-20200048267-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | CYP2D6 4092/4885ALDH1A1 3839/4885CYP3A4 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.